Eli Lilly CEO Dave Ricks stated in a CNBC interview that the company opposes the White House's push to codify 'most favored nation' drug pricing into law, despite previously signing deals with the Trump administration to align U.S. prescription drug prices with those in other wealthy nations [1]. President Donald Trump has criticized the high cost of medicines in the U.S., arguing that Americans subsidize lower prices abroad, and has advocated for legislative action to address this issue [1].
The pharmaceutical industry, including Eli Lilly, initially believed that the agreements with the Trump administration would alleviate concerns and prevent the formalization of 'most favored nation' pricing into law. However, recent efforts by the White House to push Congress to codify elements of these deals have prompted opposition from Eli Lilly [1]. The draft text of the proposed legislation has not been made public, but the administration has indicated its intention to involve pharmaceutical companies in the process [1].
Ricks expressed concerns about the legislative process, stating, 'When you throw it into the congressional process, what goes in is not what's going to come out,' and warned that prioritizing price reductions could jeopardize future innovation and the robustness of the U.S. drug industry [1]. He emphasized that Eli Lilly has communicated its opposition to both the administration and congressional leaders and will use 'all the tools we have to combat bad policy' [1].
While Ricks noted that the Trump administration and congressional leadership appear to be receptive to the company's concerns, he reiterated Eli Lilly's stance against codifying the deals, citing potential negative impacts on research and development in the pharmaceutical sector [1].
CONCLUSION
Eli Lilly's public opposition to codifying 'most favored nation' drug pricing deals signals industry resistance to legislative efforts aimed at reducing U.S. drug prices. The company's stance highlights concerns about potential impacts on innovation and the future of the American pharmaceutical sector. Market participants may view this as a medium-impact event, given the ongoing policy uncertainty and its implications for drugmakers like Eli Lilly.